A $133 billion market by 2035 — and the label performance and compliance it demands
GLP‑1 receptor agonists such as semaglutide and tirzepatide are peptide-based biologic medications that regulate blood sugar and appetite, creating a huge growth opportunity for label converters. Market forecasts project the global GLP‑1 drug market will reach $133 billion by 2035.
Unlike traditional chemical medicines, these biologics are extremely temperature-sensitive and require strict 2°C to 8°C refrigeration throughout storage and transit. Temperature deviations will permanently damage protein structures: heat triggers chemical degradation while freezing causes protein denaturation and total loss of efficacy. Worse, degraded GLP‑1 products look visually intact but offer no therapeutic value.
Industry data shows temperature excursions cost biopharma firms $35 billion annually from wasted inventory, official investigations and compliance penalties. To avoid recalls and safety risks, the FDA and USP mandate fully validated, end-to-end cold-chain traceability supported by reliable labeling.
Standard adhesives lose tack and flexibility at low temperatures, resulting in edge lifting, partial delamination or full label drop-off on small vials and injection pens. Frequent condensation when cold goods meet ambient air ruins paper labels, causing ink bleeding, wrinkling and unreadable text. Temperature cycling and abrasion also damage 2D barcodes, QR codes and serialization data critical for traceability.
As a solution, polyethylene and polypropylene film facestocks paired with cryogenic-grade acrylic adhesives are widely adopted. They resist moisture, maintain stable dimensions and help ensure consistent barcode scannability across all transport stages.
Pharmaceutical brands often apply primary and secondary labels as dual backups to lower risk, though overlap-free integrated labeling cuts packaging costs. Converters should also conduct compatibility tests with temperature loggers and prepare contingency plans for printing errors or material shortages.
The last-mile delivery phase poses the biggest threat to labels due to drastic temperature shifts and rough handling, so materials must sustain strong adhesion and legibility through all transitions. Any label malfunction may lead to shipment holds, regulatory probes and costly product recalls.
Converters who develop cold-chain-optimized label constructions with superior low-temperature adhesion, condensation resistance and full regulatory compliance will gain a competitive edge to capture the fast-expanding GLP‑1 pharmaceutical market.
← All insights